HomeTop MoversThis is what behind Immunovant Inc. (IMVT) stock dramatic drop in the...

This is what behind Immunovant Inc. (IMVT) stock dramatic drop in the premarket trading session

In the premarket session, Immunovant Inc. (IMVT) stock was trading in the red as it fell dramatically 60% to $17.00. Meanwhile, a stock recorded a -12.22% loss in the past month and a 91.51% gain in the past six months. Recent volatility for IMVT is estimated to have been 8.25% in the past week and 6.59% in the past month.

Get the hottest stocks to trade every day before the market opens 100% free. Click here now.  

What happened recently…


Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '22.
Small-cap Uranium stocks are booming in 2022! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here. .

Sponsored


Today, it was revealed that in the ongoing clinical trials for IMVT-1401, Immunovant (Nasdaq: IMVT) announced a voluntary pause in dosing.

Read More

The Company has observed elevated total cholesterol and low-density lipoprotein cholesterol levels in IMVT-1401-treated patients in ASCEND GO-2, a Phase 2b trial in Thyroid Eye Disease (TED). A previous clinical trial involving IMVT-1401 in Myasthenia Gravis (MG) and controls did not include any cholesterol levels measurement. To be cautious, the Company will adjust the monitoring procedure for both TED and Warm Autoimmune Hemolytic Anemia while educating patients, investigators, and regulators.

To learn more about the mechanism of these lipid changes and their effect across indications, the Company will work closely with regulators and scientific experts. With the consent of regulators, the Company aims to continue developing IMVT-1401.

Get the hottest stocks to trade every day before the market opens 100% free. Click here now.  

On February 2 at 8:00 EST, Immunovant will host a conference call. ​Following prepared remarks, the call will include a live question-and-answer session for the investment community.

Related Videos

Must Read

Related News

LEAVE A REPLY

Please enter your comment!
Please enter your name here